A field trial was canied outon60 volunteers selected in Yazd province, central Iran, with a vaccine containing killed promastigotes of L. major prepared by the Razi Institute, Hessarak. During these phase I studies which lasted for more than two years, we examined acceptable doses of the vaccine alone or mixed with BCG. The results so far indicate that 50 to 1000 µg of the vaccine alone can...

a field trial was canied outon60 volunteers selected in yazd province, central iran, with a vaccine containing killed promastigotes of l. major prepared by the razi institute, hessarak. during these phase i studies which lasted for more than two years, we examined acceptable doses of the vaccine alone or mixed with bcg. the results so far indicate that 50 to 1000 µg of the vaccine alone can be ...

Vaccine candidates, including live and/or killed parasites, Leishmania-purified fractions, defined recombinant antigens and antigen-encoding DNA-plasmids have been proposed to use as vaccine anti-Leishmania. More recently, the hamsters have been used to pre-selection of antigens candidate to apply in further experiments using canine model. In this report we evaluated the kinetics of cell migrat...

Leishmaniasis affects 12 million people, but there are no vaccines. Immunological correlates of vaccine efficacy are unclear. Polarized Th1 vs Th2 responses in Leishmania major-infected mice suggested that a shift in balance from IL-4 to IFN-gamma was the key to vaccine success. Recently, a role for IL-10 and regulatory T cells in parasite persistence was demonstrated, prompting re-evaluation o...

Leishmania parasites cause a spectrum of diseases that afflict the populations of 88 countries around the world and all attempts to control leishmaniasis have failed. It seems that preparing a vaccine may be the final solution. The aim of this study was to determine various Leishmania (L.) major antigens vaccine candidates and effects of the vaccine on delayed type hypersensitivity (DTH). Many ...

In the last decade, the search for new vaccines against canine visceral leishmaniasis has intensified. However, the pattern related to immune protection during long periods after experimental infection in vaccine trials is still not fully understood. Herein, we investigated the immunogenicity and parasitological levels after intradermal challenge with Leishmania infantum plus salivary gland ext...

Visceral leishmaniasis (VL) is a vector-borne disease transmitted by phlebotomine sand flies and remains the most serious form of the disease with no available human vaccine. Repeatedly, studies have demonstrated the immunogenicity and protective efficacy of a number of sand fly salivary proteins against cutaneous and visceral leishmaniasis. All Leishmania species including agents of VL are co-...

Hepatitis C virus (HCV) envelope glycoproteins E1 and E2 are the main inducers of a cross-neutralizing antibody response which plays an important role in the early phase of viral infection. Correctly folded and immunologically active E1E2 complex can be expressed in mammalian cells, though the production process might still prove restrictive, even if the immunological response of a vaccine cand...

leishmaniases are a group of sand fly-borne diseases caused by protozoan parasites from species of leishmania genus. these diseases are reported in about 100 countries with a prevalence of 12 million people infected and incidence of 2 million people per year, putting approximately 350 million people at risk of the infections. leishmaniases are endemic and are considered as important public heal...

Dogs represent the most important domestic reservoir of L. chagasi (syn. L. infantum). A vaccine against canine visceral leishmaniasis (CVL) would be an important tool for decreasing the anxiety related to possible L. chagasi infection and for controlling human visceral leishmaniasis (VL). Because the sand fly salivary proteins are potent immunogens obligatorily co-deposited during transmission...